Table 1 Comparison of clinicopathological factors between the asymptomatic and symptomatic groups (all cases).

From: Prognosis of asymptomatic versus symptomatic metastatic breast cancer: a multicenter retrospective study

 

Asymptomatic MBC

(n = 114)

Symptomatic MBC

(n = 90)

p-value

Agea, years

59.5 (36–88)

59 (26–91)

0.93

Recurrence-free survival, months

40.5 (4–237)

41 (4–309)

0.99

Visceral metastasisa

70 (61.4%)

48 (53.3%)

0.32

Multiple metastatic sitesa

40 (35.1%)

48 (53.3%)

0.01

Metastasis siteb

Lung

46

29

0.25

Bone

40

36

0.56

Lymph node

33

36

0.10

Liver

32

15

0.07

Chest wall

3

17

 < 0.001

Brain

4

7

0.22

Stage 0/1/2/3

1/22/44/43/4

0/12/48/26/4

0.49

Subtype

Luminal/HER2/Triple negative

75/27/12

45/23/22

0.02

  1. HER2 human epidermal growth factor receptor 2, MBC metastatic breast cancer.
  2. aAt the time of confirmation of metastasis
  3. bThere are duplicate cases.